RARG and erythroleukemia: Our work is the first to demonstrate that treatment with the RARγ specific agonist augments cellular adhesion in a time- and concentration- dependent manner to α5β1 integrin substrates, increases cell surface levels of the β1 integrin subunit, and dampens cellular proliferation in a time and concentration dependent manner in a human erythroleukemia cell line.